Acquired by Chiesi Farmaceutici S.p.A in May 2023
AMYT - Amryt Pharma plc
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Dublin,
Ireland
Type: Equity
AMYT price evolution
AMYT
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $83.4 | $90.73 | $102.22 | $113.03 |
| Short term investments | ||||
| Net receivables | $50.81 | $50.43 | $47.37 | $53.91 |
| Inventory | $90.24 | $124.19 | $120.06 | $115.77 |
| Total current assets | $224.45 | $265.35 | $269.64 | $282.71 |
| Long term investments | ||||
| Property, plant & equipment | $6.74 | $7.11 | $7.11 | $7.42 |
| Goodwill & intangible assets | $503.94 | $490.52 | $508.26 | $491.36 |
| Total noncurrent assets | $512.43 | $499.4 | $517.22 | $500.66 |
| Total investments | ||||
| Total assets | $736.88 | $764.74 | $786.87 | $783.37 |
| Current liabilities | ||||
| Accounts payable | $134.95 | $127.91 | $136.75 | $149.73 |
| Deferred revenue | ||||
| Short long term debt | $5.72 | |||
| Total current liabilities | $143.14 | $151.03 | $143.71 | $157.28 |
| Long term debt | $208.6 | $207.06 | $205.51 | $199.18 |
| Total noncurrent liabilities | $269.45 | $271.68 | $297.18 | $288.64 |
| Total debt | $208.6 | $212.78 | $205.51 | $199.18 |
| Total liabilities | $412.6 | $422.71 | $440.88 | $445.92 |
| Shareholders' equity | ||||
| Retained earnings | -$271.39 | -$248.69 | -$246.68 | -$252.47 |
| Other shareholder equity | ||||
| Total shareholder equity | $324.28 | $342.03 | $345.98 | $337.45 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $113.03 | $118.8 | $67.23 | $31.88 |
| Short term investments | ||||
| Net receivables | $53.91 | $43.19 | $36.39 | $28.91 |
| Inventory | $115.77 | $40.99 | $43.62 | $48.95 |
| Total current assets | $282.71 | $202.97 | $147.24 | $88.83 |
| Long term investments | ||||
| Property, plant & equipment | $7.42 | $7.57 | $3.04 | $1.4 |
| Goodwill & intangible assets | $491.36 | $324.5 | $381.77 | $200.18 |
| Total noncurrent assets | $500.66 | $333.62 | $387.11 | $238.98 |
| Total investments | ||||
| Total assets | $783.37 | $536.59 | $534.35 | $327.81 |
| Current liabilities | ||||
| Accounts payable | $149.73 | $90.24 | $76.6 | $16 |
| Deferred revenue | ||||
| Short long term debt | $385.76 | |||
| Total current liabilities | $157.28 | $101.17 | $100.21 | $455.8 |
| Long term debt | $199.18 | $188.39 | $178.47 | $19.01 |
| Total noncurrent liabilities | $288.64 | $369.27 | $304.81 | $20.19 |
| Total debt | $199.18 | $188.39 | $178.47 | $385.76 |
| Total liabilities | $445.92 | $470.45 | $405.02 | $475.99 |
| Shareholders' equity | ||||
| Retained earnings | -$252.47 | -$235.6 | -$133.67 | -$206.22 |
| Other shareholder equity | $236.49 | $248.63 | -$1.33 | |
| Total shareholder equity | $337.45 | $66.14 | $129.32 | -$148.17 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $61.13 | $68.54 | $59.13 | $54.83 |
| Cost of revenue | $33.7 | $33.36 | $30.77 | $29.19 |
| Gross Profit | $27.42 | $35.17 | $28.35 | $25.64 |
| Operating activities | ||||
| Research & development | $8.01 | $10.67 | $9.88 | $9.28 |
| Selling, general & administrative | $26.98 | $28.23 | $27.71 | $29.56 |
| Total operating expenses | $37.89 | $42.05 | $41.14 | $76.16 |
| Operating income | -$10.47 | -$6.88 | -$12.79 | -$50.52 |
| Income from continuing operations | ||||
| EBIT | -$11.74 | -$0.19 | -$13.89 | $33.2 |
| Income tax expense | $2.69 | $0.1 | -$10.53 | $3.09 |
| Interest expense | $6.36 | $6.76 | $11.13 | $7.74 |
| Net income | ||||
| Net income | -$20.8 | -$7.05 | -$14.49 | $22.37 |
| Income (for common shares) | -$20.8 | -$7.05 | -$14.49 | $22.37 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $222.54 | $182.61 | $58.12 | $130.43 |
| Cost of revenue | $106.12 | $119.03 | $42 | $59.7 |
| Gross Profit | $116.42 | $63.58 | $16.12 | $70.73 |
| Operating activities | ||||
| Research & development | $37.73 | $27.62 | $15.83 | $38.06 |
| Selling, general & administrative | $92 | $76.67 | $35.5 | $64.44 |
| Total operating expenses | $187.63 | $110.04 | $69.87 | $105.61 |
| Operating income | -$71.21 | -$46.46 | -$53.75 | -$34.88 |
| Income from continuing operations | ||||
| EBIT | -$1.91 | -$86.29 | -$62 | -$41.1 |
| Income tax expense | -$11.64 | -$1.33 | -$1.23 | $1.71 |
| Interest expense | $27.91 | $19.57 | $4.76 | $53.73 |
| Net income | ||||
| Net income | -$18.17 | -$104.53 | -$65.53 | -$96.54 |
| Income (for common shares) | -$18.17 | -$104.53 | -$65.53 | -$96.54 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$20.8 | -$7.05 | -$14.49 | $22.37 |
| Operating activities | ||||
| Depreciation | $16.98 | $14.87 | $14.83 | $15.51 |
| Business acquisitions & disposals | -$16.21 | |||
| Stock-based compensation | $2.9 | $2.88 | $3.15 | $2.44 |
| Total cash flows from operations | $14.34 | -$5.96 | -$7.54 | $107.42 |
| Investing activities | ||||
| Capital expenditures | -$0.33 | -$0.24 | -$0.42 | -$0.62 |
| Investments | ||||
| Total cash flows from investing | -$16.43 | -$0.22 | -$0.42 | -$0.62 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$1.95 | $1.06 | $4.82 | |
| Net borrowings | -$0.3 | -$3.6 | $2.57 | -$117.06 |
| Total cash flows from financing | -$5.06 | -$3.48 | -$2.67 | -$116.92 |
| Effect of exchange rate | -$0.18 | -$1.83 | -$0.17 | -$0.03 |
| Change in cash and equivalents | -$7.33 | -$11.49 | -$10.81 | -$10.14 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$18.17 | -$104.53 | -$65.53 | -$96.54 |
| Operating activities | ||||
| Depreciation | $50.74 | $44.47 | $12.65 | $26.67 |
| Business acquisitions & disposals | $107.94 | $24.98 | ||
| Stock-based compensation | $8.34 | $4.73 | $0.84 | $1.47 |
| Total cash flows from operations | $15.53 | $26.89 | -$37.5 | -$38.76 |
| Investing activities | ||||
| Capital expenditures | -$1.54 | -$2.47 | -$0.65 | -$0.44 |
| Investments | ||||
| Total cash flows from investing | $106.4 | -$2.38 | $24.43 | -$0.44 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $4.7 | $37.93 | $63.01 | |
| Net borrowings | -$117.84 | -$1.12 | $9.19 | $58.53 |
| Total cash flows from financing | -$125.43 | $26.03 | $65.94 | $58.53 |
| Effect of exchange rate | -$2.27 | $1.03 | $3.13 | -$1.76 |
| Change in cash and equivalents | -$5.77 | $51.57 | $56 | $17.57 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $243.62M |
|---|---|
| EBITDA | $69.55M |
| EBIT | $7.38M |
| Net Income | -$19.96M |
| Revenue Q/Q | 8.15% |
| Revenue Y/Y | 15.88% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -2.60% |
| ROE | -5.92% |
| Debt/Equity | 1.32 |
|---|---|
| Net debt/EBITDA | 4.73 |
| Current ratio | 1.57 |
| Quick ratio | 0.94 |